Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by this ambitious company and documents Biomm’s vision to develop a balanced portfolio combining very innovative biologicals and leading biosimilars in order to maximize the access scenario of the Brazilian healthcare ecosystem.
You indisputably stand as one of the most respected Brazilian executives in the pharmaceutical sector after having honed a prestigious experience among leading multinational companies, including the position of SVP Latin America at Sanofi. Which key specificities of Biomm motivated you to embrace this new challenge in your career?
"The biotech industry is very important for the innovation-oriented development of Brazil, our country should definitely allocate more resources to the dawn of this sector."
